Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02967133 · ClinicalTrials.gov registry record · Phase 2
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Alliance Foundation Trials.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT02967133 is a Phase 2 study that was terminated before completion, run by Alliance Foundation Trials. The registered enrollment target is 7 participants.
The verdict
NCT02967133, a Phase 2 study, was terminated before completion, sponsored by Alliance Foundation Trials.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The optimal prioritization of second-line chemotherapy and immune therapy based on demographic or biomarker data is an area of ongoing investigation. The hypothesis of this study is that there may be an additive or synergistic antitumor effect of combined chemotherapy and nivolumab in the second-line treatment of NSCLC as an important concept to test in a clinical trial. Previously treated NSCLC remains a setting of unmet clinical need despite recent clinical research progress. Early progression for a subset of NSCLC patients receiving nivolumab is a specific area of clinical need.
Interventions
- DRUG Nivolumab
- DRUG nab-paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-12 |
| Est. Completion | 2018-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02967133
The ClinicalTrials.gov registry entry for NCT02967133 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance Foundation Trials, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02967133 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02967133 about?
NCT02967133 is a clinical study titled "A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer". The optimal prioritization of second-line chemotherapy and immune therapy based on demographic or biomarker data is an area of ongoing investigation. The hypothesis of this study is that there may be an additive or synergistic antitumor effect of combined chemotherapy and nivolumab in the second-lin...
What is the current status of trial NCT02967133?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2016-12. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02967133?
The interventions under investigation include: Nivolumab (DRUG), nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02967133?
This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.